Weight loss jabs could help cut alcohol consumption, study suggests
Weight loss jabs could help slash alcohol intake in obese people by around two thirds, according to a study.
It is thought the drugs help curb cravings for alcohol, experts said, although more research is needed.
Weight loss jabs, also known as GLP-1 receptor agonists, work by reducing food cravings.
The study, led by academics in Ireland and Saudi Arabia, included 262 obese people who had been prescribed liraglutide or semaglutide, which are available under the brand names Saxenda and Wegovy respectively.
They were categorised based on the amount of alcohol they consumed each week prior to starting treatment.
The groups included non-drinkers, rare drinkers who had less than 10 units a week, and regular drinkers, who reported having 10 or more units each week.
Some 188 of the 262 patients were followed up for an average of four months.
Average alcohol consumption fell from 11.3 units a week – about six or seven pints of beer – to 4.3 units a week, or roughly two pints of beer, after four months on the drugs.
Among regular drinkers, intake decreased by 68%, from 23.2 units a week to 7.8 units a week.
Professor Carel le Roux, of University College Dublin, said: 'The exact mechanism of how GLP-1 analogues reduce alcohol intake is still being investigated but it is thought to involve curbing cravings for alcohol that arise in subcortical areas of the brain that are not under conscious control.
'Thus, patients report the effects are 'effortless'.'
The findings, which are being presented at the European Congress on Obesity in Malaga, suggest a 'potential therapeutic role' for weight loss jabs in people who are obese and regularly drink alcohol, researchers said.
However, they stressed larger trials are needed to validate the results.
Prof Le Roux added: 'GLP-1 analogues have been shown treat obesity and reduce the risk of multiple obesity-related complications.
'Now, the beneficial effects beyond obesity, such as on alcohol intake, are being actively studied, with some promising results.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
an hour ago
- New York Post
Weight loss drugs like Ozempic could mess with your birth control — and get you pregnant
A UK watchdog is urging women on GLP-1 weight-loss drugs like Ozempic and Mounjaro to use effective forms of birth control after receiving more than 40 pregnancy-related reports linked to the medications. The warning comes as women flood social media with stories of their so-called 'Ozempic babies' — including surprise pregnancies while on the pill. Trying to shed pounds, not grow a baby bump? Here's what you need to know about GLP-1s, pregnancy and the best contraception options to stay protected. 4 Studies show that at least one in eight US adults have tried GLP-1s. íÅí°íâ¬í¸í½í° íâíµí¼íµíËí°í¾ – What's in your GLP-1? Several GLP-1 drugs dominate the market, including Ozempic and Wegovy. Both contain semaglutide, an active ingredient that mimics a natural hormone in the body that boosts insulin production, slows digestion and curbs appetite. Then there's Saxenda and Victoza, powered by liraglutide, which functions in a similar way. Newer drugs like Mounjaro and Zepbound rely on tirzepatide, a key ingredient that targets a second hormone involved in appetite and blood sugar control. A surprise side effect While gastrointestinal symptoms like nausea, vomiting and diarrhea are common with GLP-1s, the surprise side effect making waves is unexpected pregnancy. The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has received 28 reports related to pregnancy in patients on tirzepatide, and nine each for semaglutide and liraglutide. 4 Women on tirzepatide-based GLP-1s should use barrier contraception. nenetus – In an alert this week, the agency warned that tirzepatide may reduce the effectiveness of oral contraceptives, especially in women with higher body weight. As a result, it recommended using barrier methods like condoms while on drugs like Mounjaro. So far, there's no evidence that GLP-1s affect non-oral birth control like IUDs, implants, patches, or rings, according to the UK's Faculty of Reproductive Healthcare. And yes, the advice applies even to women previously told they were infertile. GLP-1s have been shown to boost fertility by aiding weight loss, reducing inflammation and improving insulin sensitivity — leading some to conceive just months after starting treatment. 4 GLP-1 agonists can increase your fertility, but they can also interfere with pregnancy. Louis-Photo – Can you take GLP-1s while pregnant? Experts say no — at least not yet. There's not enough data to confirm whether GLP-1s are safe during pregnancy. While a some human studies suggests there is no harm in first-trimester use, testing in animals has shown the drugs could increase the risk of miscarriage and birth defects. 4 Scientists are still working to understand whether GLP-1s can negatively impact a developing fetus. Evrymmnt – Another reason to skip GLP-1s while pregnant: they suppress your appetite and can trigger gastrointestinal issues, which may lead to nutrient deficiencies that impact fetal development. The drugs should also be avoided during breastfeeding, since there's not enough research to confirm safety for infants. Trying to conceive? Here's the timeline If you're planning to get pregnant, the MHRA recommended stopping GLP-1s before you start trying to conceive and giving your body time to clear the drugs. For semaglutide users, that means quitting at least two months ahead. If you're on tirzepatide, stop one month before trying. Liraglutide clears the system faster, so you can stop right before you start trying to conceive.
Yahoo
5 hours ago
- Yahoo
Novo Nordisk Stock: Is It Still a Smart Buy?
This one-time weight-loss drug leader has suffered several setbacks lately. It isn't wise to count out this veteran pharmaceutical company, however. 10 stocks we like better than Novo Nordisk › Much like the long-term users of its most popular product, Novo Nordisk's (NYSE: NVO) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight loss drug Wegovy, have fallen nearly 18% in price since the start of this year. Popularity attracts competition, and investors are growing concerned that the Danish pharmaceutical giant won't be able to compete. I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, when Wegovy became the first GLP-1 drug specifically approved by the Food and Drug Administration (FDA) for that indication in mid-2021. Novo Nordisk's Ozempic was first, but it was used off-label as a weight-loss drug, and had only initially been approved as a diabetes treatment and kidney disease treatment. It's easy to believe in a company when it's riding high and unopposed. But late in 2023, a new entrant was approved -- mighty American pharmaceutical company Eli Lilly (NYSE: LLY) with its own GLP-1 treatment, Zepbound -- giving Novo Nordisk one of the strongest competitors imaginable. Almost certainly, this won't continue to be a two-car race for long. Other companies, both large and small, in the healthcare field are pushing hard to develop their own obesity drugs, with varying degrees of success. Eli Lilly alone is an intimidating presence. A mainstay on the American pharmaceutical scene, it's grown to a massive size, to the point where it's the most valuable pharmaceutical company in the world by market cap. It can leverage its vast resources to develop and market any kind of medicine it wants, and in the obesity segment, it was already nearly there with Zepbound's FDA-approved-for-diabetes sibling drug, Mounjaro. Since then, it seems Zepbound has carved out a significant market share from Wegovy. Precise figures are hard to come by, but according to a Goldman Sachs analysis recently reported by Barron's, Novo Nordisk is clinging to a 51% share of the roughly $28 billion market. Eli Lilly holds the rest. Like other pharmaceutical industry pundits, Goldman Sachs is predicting that once other obesity drugs are developed successfully and approved, the market will fragment. That's a wholly believable prediction given the zeal and urgency behind many of those efforts. Meanwhile, Novo Nordisk has taken a series of competitive blows that reduced its lead. A shortage of semaglutide -- the main ingredient of Wegovy -- led the FDA to allow compounding pharmacies to make copies of the molecule, essentially producing new competition. Although the shortage is officially over, it showed that Novo Nordisk would be vulnerable if such a situation reoccurred. Another of the numerous fresh setbacks was a head-to-head clinical trial conducted by Eli Lilly, pitting Zepbound against Wegovy. Last December, the results of the study indicated notably more significant weight loss for participants using Wegovy. One internal development also dented investor sentiment on Novo Nordisk, and that was the company's announcement in mid-May that long-serving CEO Lars Fruergaard Jørgensen was stepping down. When enterprises are humming along pleasantly, they rarely experience a top leader's departure. Novo Nordisk isn't just absorbing hurtful blows, though; it's been busy shoring up its defenses. As 2024 came to a close, it scooped up contract drug manufacturer Catalent, bringing Wegovy production more under its direct control. That $16.5 billion deal wasn't cheap by any yardstick, but if the new asset is managed well, it should be more than worth the cost ultimately. Novo Nordisk is also keeping up the pace with its own development activities, attempting to succeed with new medications and/or other indications for Wegovy. Its next-generation obesity treatment CagriSema was essentially a flop. However, the company has already had success winning FDA approval for the versatile Wegovy to treat liver disorder metabolic dysfunction-associated steatohepatitis (MASH), and it's developing the drug for a clutch of other ailments. It also has other medications for different disorders in its pipeline. Meanwhile, a score of researchers modeling the future of the obesity market feel that sales of such drugs will blast through the roof. Projections vary, but a typical one is the latest from Morgan Stanley. In May, the veteran investment bank upped its estimate for the market's peak (predicted to occur in 2035) to $150 billion, well up from its previous assumption of $105 billion. The former number is more than 6 times the $24 billion estimated sales of 2024. The very encouraging news for Novo Nordisk bulls like myself is that even if the market gets highly fragmented with numerous competing products and loses significantly more share -- unlikely, given its first-mover prominence and the strength of the Wegovy brand name -- it'll still be a player in a huge market. Yes, competition can be tough. There are a lot of prizes in this game, and more players are entering it. But I think this original player will manage to hold on and thrive, and I continue to consider Novo Nordisk stock a buy. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Goldman Sachs Group. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Novo Nordisk Stock: Is It Still a Smart Buy? was originally published by The Motley Fool
Bloomberg
7 hours ago
- Bloomberg
Lilly's Obesity Drug Sales Rise 60% in India Amid Rising Demand
Eli Lilly & Co. increased sales of weight-loss and diabetes drug Mounjaro 60% in India in May from April in its second full month of being on offer in the South Asian country, which has the world's third-highest number of obese people. The US drugmaker sold 126 million rupees ($1.5 million) worth of the injections last month, according to market analysis firm Pharmarack Technologies. Sales of its 5 mg version more than doubled to about 75 million rupees, while revenue from the 2.5 mg shot was 51 million rupees.
